These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 5580101)

  • 1. Effect of L-dopa on brain monoamines and their metabolites in Parkinson's disease.
    Rinne UK; Sonninen V; Hyyppä M
    Life Sci I; 1971 May; 10(10):549-57. PubMed ID: 5580101
    [No Abstract]   [Full Text] [Related]  

  • 2. L-DOPA treatment in Parkinson's disease: effect on dopamine and related substances in discrete brain regions.
    Davidson L; Lloyd K; Dankova J; Hornykiewicz O
    Experientia; 1971 Sep; 27(9):1048-9. PubMed ID: 5116129
    [No Abstract]   [Full Text] [Related]  

  • 3. Distribution of norepinephrine, epinephrine, dopamine, serotonin, 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindole-3-acetic acid in dog brain.
    Mefford IN; Foutz A; Noyce N; Jurik SM; Handen C; Dement WC; Barchas JD
    Brain Res; 1982 Mar; 236(2):339-49. PubMed ID: 6175382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biogenic amines in discrete brain areas after treatment with monoamineoxidase inhibitors.
    Valzelli L; Garattini S
    J Neurochem; 1968 Mar; 15(3):259-61. PubMed ID: 5638622
    [No Abstract]   [Full Text] [Related]  

  • 5. Levels and distribution of central nervous system amines in normal and morphine-dependent monkeys.
    Segal M; Deneau GA; Seevers MH
    Neuropharmacology; 1972 Mar; 11(2):211-22. PubMed ID: 4623661
    [No Abstract]   [Full Text] [Related]  

  • 6. [Analysis of monoamines of the locus ceruleus and other cerebral structures by thin layer chromatography].
    Gérardy J; Quinaux N; Maeda T; Dresse A
    Arch Int Pharmacodyn Ther; 1969 Feb; 177(2):492-6. PubMed ID: 5807181
    [No Abstract]   [Full Text] [Related]  

  • 7. Cerebral catecholamine concentration after L-dopa therapy in Parkinson's disease.
    Greer M; Anton AH
    Trans Am Neurol Assoc; 1970; 95():247-8. PubMed ID: 4328099
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH; Bowers MB
    Experientia; 1970; 26(2):161-3. PubMed ID: 5308739
    [No Abstract]   [Full Text] [Related]  

  • 9. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W
    Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
    [No Abstract]   [Full Text] [Related]  

  • 10. On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.
    Casati C; Agnoli A; Jori A; Dolfini E
    Z Neurol; 1973 Apr; 204(2):149-54. PubMed ID: 4121468
    [No Abstract]   [Full Text] [Related]  

  • 11. [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].
    Pletscher A; Bartholini G; Gey KF; Jenni A
    Schweiz Med Wochenschr; 1970 May; 100(19):797-804. PubMed ID: 4924275
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of ethanol on the effects of DL-p-chlorophenylalanine on biogenic amines of rat brain.
    Jofre de Breyer IJ; Acevedo C; Torrelio M
    Arzneimittelforschung; 1972 Dec; 22(12):2140-2. PubMed ID: 4267750
    [No Abstract]   [Full Text] [Related]  

  • 13. Regional concentrations of serotonin, tryptophan, 5-hydroxyindoleacetic acid, dopamine, and norepinephrine in the ovine brain.
    Baber KA; Meyers KM; Clemmons R; Peters R
    Am J Vet Res; 1979 Oct; 40(10):1378-80. PubMed ID: 525857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa].
    Buscaino GA; Sori A; Campanella G
    Rev Neurol (Paris); 1972 Aug; 127(2):301-2. PubMed ID: 4666634
    [No Abstract]   [Full Text] [Related]  

  • 15. Simultaneous extraction and fluorometric measurement of brain serotonin, catecholamines, 5-hydroxy-indoleacetic acid and homovanillic acid.
    Haubrich DR; Denzer JS
    Anal Biochem; 1973 Sep; 55(1):306-12. PubMed ID: 4753155
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dopaminergic conception of Parkinsonism and its treatment with L-DOPA].
    Levin SL
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(9):1418-26. PubMed ID: 4349303
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopaminergic nervous transmission in Parkinson's disease.
    Rinne UK; Sonninen V; Riekkinen P; Laaksonen H
    Med Biol; 1974 Jun; 52(3):208-17. PubMed ID: 4371255
    [No Abstract]   [Full Text] [Related]  

  • 18. Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V
    Arch Neurol; 1973 Feb; 28(2):107-10. PubMed ID: 4683147
    [No Abstract]   [Full Text] [Related]  

  • 19. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B; Roos BE
    Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
    [No Abstract]   [Full Text] [Related]  

  • 20. Dopaminergic supersensitivity in parkinsonism.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    Adv Neurol; 1975; 9():121-9. PubMed ID: 1146650
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.